This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 5, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ALVO preps for Q2 results as investors eye early U.S. traction for Simlandi and Selarsdi, plus pipeline progress.
RDYNegative Net Change AMGNPositive Net Change TEVAPositive Net Change ALVONegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
by Ahan Chakraborty
Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising competition.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
by Ekta Bagri
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech
ILMNNegative Net Change BEAMPositive Net Change EDITPositive Net Change NTLAPositive Net Change PRMEPositive Net Change CRSPPositive Net Change
biotechnology biotechs gene-editing gene-therapy genetics genomics medical pharmaceuticals
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
by Zacks Equity Research
AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.
PFENegative Net Change AMGNPositive Net Change CRMDPositive Net Change DNLIPositive Net Change
biotechs
Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?
by Ekta Bagri
Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets.
BMYNegative Net Change MRKNegative Net Change AMGNPositive Net Change
biotechnology biotechs medical pharmaceuticals
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
by Zacks Equity Research
Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
NVSPositive Net Change LLYPositive Net Change BAYRYNegative Net Change INCYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
by Zacks Equity Research
EXEL beats on Q2 earnings but misses revenues as lower collaboration income offsets strong Cabometyx sales growth.
RHHBYNegative Net Change BMYNegative Net Change EXELPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and Alyftrek and Journavx launches.
VRTXPositive Net Change CRMDPositive Net Change EXASNegative Net Change CRSPPositive Net Change
biotechs
Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?
by Zacks Equity Research
MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.
MRKNegative Net Change MRNAPositive Net Change EXASNegative Net Change BNTXPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?
by Sundeep Ganoria
ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.
RHHBYNegative Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs earnings-preview medical pharmaceuticals
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.
ALKSNegative Net Change VRTXPositive Net Change EXASNegative Net Change CRSPPositive Net Change
biotechs
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
by Ahan Chakraborty
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
AZNPositive Net Change BMYNegative Net Change MRKNegative Net Change MRNAPositive Net Change ABBVPositive Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals vaccines
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.
BIIBNegative Net Change LLYPositive Net Change SUPNPositive Net Change SAGENo Net Change
biotechs
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
by Ekta Bagri
BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.
BMYNegative Net Change PFENegative Net Change BNTXPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility
by Shrabana Mukherjee
New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.
GHMPositive Net Change HWKNNegative Net Change KALANegative Net Change ARQNegative Net Change
biotechs industrial-products
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
by Ahan Chakraborty
Recursion Pharmaceuticals and Relay Therapeutics both leverage their respective AI drug discovery platforms to potentially develop novel therapeutic candidates.
SNYNegative Net Change RHHBYNegative Net Change RLAYPositive Net Change RXRXPositive Net Change
artificial-intelligence biotechnology biotechs medical pharmaceuticals
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
by Zacks Equity Research
Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.
REGNPositive Net Change VRTXPositive Net Change MRNAPositive Net Change HRMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.
ALKSNegative Net Change AMRNNegative Net Change EXASNegative Net Change AKROPositive Net Change
biotechs
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
NVSPositive Net Change INCYPositive Net Change EXASNegative Net Change AKROPositive Net Change
biotechs
Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues
by Zacks Equity Research
RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
RDYNegative Net Change MRKNegative Net Change AMGNPositive Net Change ALVONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
by Zacks Equity Research
Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.
AGENPositive Net Change AMRNNegative Net Change VKTXPositive Net Change AKROPositive Net Change
biotechs earnings medical
How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?
by Sundeep Ganoria
LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.
AZNPositive Net Change PFENegative Net Change MRKNegative Net Change LLYPositive Net Change
biotechs earnings medical pharmaceuticals
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
by Ekta Bagri
Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.
BMYNegative Net Change JNJPositive Net Change KROSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
by Zacks Equity Research
EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.
ALKSNegative Net Change INCYPositive Net Change EXELPositive Net Change AKROPositive Net Change
biotechnology biotechs medical pharmaceuticals